Here, we proposed a model in which TGF-β is capable of inducing tumorigenic through the reduction of miR-196a-3p, which targets NRP2, leading to its accumulation (Figure 8), providing novel potential targets for the treatment of metastatic breast cancers. The gene discussed is NRP2; the disease is breast cancer.